?? Our new episode is out now, where we chat with special guest Bishoy Morris Faltas on his work in extrachromosomal DNA in #bladdercancer from his latest Nature publication. ?? Listen on Spotify: https://lnkd.in/e2CA8N_q ?? Listen on Apple Podcasts: https://lnkd.in/egBF9U9C
The Uromigos
医疗机构
Striving to provide balanced, scientific content related to care of patients with GU malignancies.
关于我们
Led by Thomas Powles, MD, and Brian Rini, MD, FASCO, The Uromigos highlight the latest developments in genitourinary cancers. Their podcast episodes feature guest experts from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients. The Uromigos formed in early 2017 as a group of friends attempting to provide balanced, scientific content about GU malignancies on Twitter. It was hoped that this diverse group would represent various positions on a given topic, which has not always been the case on social media. This attempt was ‘moderately successful’ as Tom would say. Different viewpoints were represented, but they weren’t that good at Twitter. In early 2020, Tom and Brian decided to try their hand at podcasting. With more enthusiasm than expertise, the Uromigos podcasts were launched. Over 300 podcasts and nearly 350,000 cumulative listens later, they hope the podcasts have become a significant resource for balanced scientific content related to the care of patients with GU malignancies. Built around the conversational style of podcasts, the first Uromigos Live meeting was held in Nashville in late 2022. The foundational principles of both the live meeting and podcasts are to challenge conventional thinking, to encourage diverse and unbiased viewpoints and to promote early career researchers.
- 网站
-
https://www.uromigos.org/
The Uromigos的外部链接
- 所属行业
- 医疗机构
- 规模
- 2-10 人
- 类型
- 合营企业
动态
-
?? Episode 368 is out now - join us and Andrew Smith from St. Jude Children's Research Hospital as he leads a discussion on the emerging field of radiomics, and shares his hopes and skepticism. ?? Listen on Spotify: https://lnkd.in/ea4AUhxZ ?? Listen on Apple Podcasts: https://lnkd.in/e6Xxarih
Episode 368: Radiomics in RCC: Live from IKCS
https://spotify.com
-
?? Our latest episode with Charles Ryan of Memorial Sloan Kettering Cancer Center focuses on various aspects of AR inhibition for #prostatecancer and the treatment’s relative benefits and risks, as well as how it compares to abiraterone: https://lnkd.in/e_7r_VtC ?? While previous discussion on AR inhibitors and ARPIs has been dubbed a “Coke versus Pepsi” debate, Brian considers this new discussion comparing abiraterone with AR inhibitors as a “Fanta versus Coke” situation. ?? Which do you prefer? Listen and decide!
Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer
https://spotify.com
-
?? Listen to our latest podcast episode featuring guests Chris Sweeney and Rob Jones, featuring discussion on the merits of various ARPIs in prostate cancer: https://lnkd.in/e76sr-RE
Episode 366: ARPIs in Prostate Cancer - Are They Different?
https://spotify.com
-
?? Don't get spooked by new data - watch the #UromigosLive24 panel on novel ADCs in urothelial carcinoma discussed by Drs. Andrea Apolo, Petros Grivas, Shilpa Gupta, and Kala Sridhar. ?? Learn about a new study from Dr. Yohann Loriot of Gustave Roussy on BT8009, HER3, and more: https://lnkd.in/eAf7tFSj
#UromigosLive24 ADCs in UC Panel Part 4: Novel ADCs Including HER3 and Novel Nectin-4
https://www.youtube.com/
-
?? Will the future of papillary RCC research offer tricks, or treats? ?? ?? Watch the #UromigosLive24 panel including Hans Hammers and Laurence Albiges on forthcoming data in the field, including the role of trials comparing new combinations against traditional treatments such as sunitinib. https://lnkd.in/ehxryuy7
#UromigosLive24 Front-Line Therapy in RCC Panel Part 3: What Data is Forthcoming in Papillary RCC?
https://www.youtube.com/
-
?? Revisit #UromigosLive24 and check out the full playlist of videos from the radioligands in prostate cancer panel: https://lnkd.in/gwhZXPv2 ?? Panelists Michael Morris, Tanya Dorff, Karen Autio, and Gary Smith discuss the impact of radioligand therapy in terms of its long-term effects on patient outcomes.
#UromigosLive24 Radioligands in PCa Panel
youtube.com
-
?? Returning guests Bertrand Tombal and Silke Gillessen join the podcast in our latest episode to dive into some of the top take-home data from the 2024 Advanced Prostate Cancer Consensus Conference. ?? We also discuss Dr. Gillessen's latest publication on the management of patients with advanced #prostatecancer: https://lnkd.in/gniqc9ts ?? Listen now! ?? https://lnkd.in/e9BxygV8
Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC) by The Uromigos
podcasters.spotify.com
-
?? Check out our YouTube playlists featuring each #UromigosLive24 panel split up into convenient parts for your viewing pleasure! https://lnkd.in/erqTndAQ ?? Kick back this weekend with the IO Rechallenge panel that featured great discussion with guests @TiansterZhang, @DrChoueiri, and David McDermott: https://lnkd.in/emUje73u
The Uromigos
youtube.com
-
? Our latest episode with special guest Bertrand Tombal focuses on the historic and current data of AR inhibition and monotherapy with AR blockers. ?? The effects of enzalutamide and results of the EMBARK study are also discussed. ?? Listen now: https://lnkd.in/ejTrkM2R
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer
https://spotify.com